1. Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis 
Stephen Hanauer, Remo Panaccione, Silvio Danese, Adam Cheifetz, Walter Reinisch, Peter D.R. Higgins, Deborah A. Woodworth, Haiying Zhang, Gary S. Friedman, Nervin Lawendy, Daniel Quirk, Chudy I. Nduaka, Chinyu Su 
Clinical Gastroenterology and Hepatology 
Volume 17, Issue 1, Pages (January 2019)
DOI: /j.cgh
Copyright © 2019 AGA Institute Terms and Conditions

2. Figure 1
Proportion of patients with (A) Mayo stool frequency subscore = 0, (B) Mayo stool frequency subscore ≤1, and (C) reduction from baseline Mayo stool frequency subscore of ≥1 point, over time. Data are full analysis set, observed case. Day 0 represents data reported within 5 days before the baseline visit, and day 1 reflects the first dose of medication. Proportion of patients with reduction from baseline Mayo stool frequency subscore of ≥1 point excludes patients with baseline Mayo stool frequency subscore = 0. BID, twice daily. *P < .05. **P < .01. ***P < vs placebo.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

3. Figure 2
Proportions of patients with (A) Mayo rectal bleeding subscore = 0, (B) Mayo rectal bleeding subscore ≤1, and (C) reduction from baseline Mayo rectal bleeding subscore of ≥1 point, over time. Data are full analysis set, observed case. Day 0 represents data reported within 5 days before the baseline visit, and day 1 reflects the first dose of medication. Proportion of patients with reduction from baseline Mayo rectal bleeding subscore of ≥1 point excludes patients with baseline Mayo rectal bleeding subscore = 0. BID, twice daily. *P < .05. **P < .01. ***P < vs placebo.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions

4. Figure 3
Proportion of patients with (A) reduction from baseline Mayo stool frequency subscore of ≥1 point over time, (B) Mayo rectal bleeding subscore = 0 over time, and (C) reduction from baseline Mayo rectal bleeding subscore of ≥1 point over time, by prior anti–tumor necrosis factor (TNF) failure (yes/no). Data are full analysis set, observed case. Day 0 represents data reported within 5 days before the baseline visit, and day 1 reflects the first dose of medication. Proportion of patients with reduction from baseline Mayo stool frequency subscore of ≥1 point excludes patients with baseline Mayo stool frequency subscore = 0. Proportion of patients with reduction from baseline Mayo rectal bleeding subscore of ≥1 point excludes patients with baseline Mayo rectal bleeding subscore = 0. BID, twice daily.
Clinical Gastroenterology and Hepatology  , DOI: ( /j.cgh )
Copyright © 2019 AGA Institute Terms and Conditions